BOSTON & MONTREAL, December 30, 2024--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational ...

NYSE:PFE) Pfizer's Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer ...

BBC Sport explains how the cold temperatures can effect a football team's pre-game approach and in-game strategy.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common ...

In 2022, over 600,000 people across the world were diagnosed with bladder cancer, a 7.1% increase from 2020, putting their life plans on hold to receive standard of care treatments that are not always ...

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Colon Cancer. According to GlobalData, Phase II drugs for Colon Cancer have an 11% phase transition success ...

Complete response at either 3 or 6 months occurred in 74.5%. The median duration of response has not yet been reached, but exceeds 27 months. Intravesical cretostimogene grenadenorepvec leads to ...

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...

Pembrolizumab is under clinical development by Merck and currently in Phase II for Anal Cancer. According to GlobalData, Phase II drugs for Anal Cancer have a 19% phase transition success rate (PTSR) ...

EUREKA SPRINGS, AR – Turpentine Creek Wildlife Refuge is a sanctuary for big cats and other exotic animals in need. Since its founding in 1992, the refuge has grown into one of the nation’s premier ...